^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Proof of concept trial alternating lorlatinib with crizotinib in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

    Excerpt:
    ...Adults aged >=18 years with pathologically confirmed stage IV ALK gene rearranged NSCLC (predominately adenocarcinoma phenotype) by IHC and or FISH, fresh or archival, not required to be reconfirmed centrally...
    Trial ID:
    ACTRN12619000844145
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JTO Clin Res Rep
    Title:

    Efficacy and Tolerability of ALK/MET Combinations in Patients with ALK-Rearranged Lung Cancer with Acquired MET Amplification: A Retrospective Analysis

    Published date:
    05/31/2023
    Excerpt:
    We assembled a cohort of patients with ALK+ lung cancer and acquired MET amplification (identified by tissue or plasma) who received regimens targeting both ALK and MET....Partial responses were observed in 5 (42%) of 12 patients, including patients who received crizotinib (n=1 of 2), lorlatinib + crizotinib (n=3 of 6), and alectinib + capmatinib (n=1 of 3).
    DOI:
    https://doi.org/10.1016/j.jtocrr.2023.100534